Gluckman E, Lotsberg J, Devergie A, Zhao X M, Melo R, Gomez-Morales M, Mazeron M C, Perol Y
J Antimicrob Chemother. 1983 Sep;12 Suppl B:161-7. doi: 10.1093/jac/12.suppl_b.161.
In a double-blind controlled study, oral acyclovir has been compared to a placebo in a series of 39 consecutive patients undergoing bone marrow transplantation. A dose of 200 mg was given every 6 h from day 8 to day 35 after transplantation. Pharmacokinetic studies have shown the good absorption of the drug despite intestinal damage related to chemoradiotherapy or gut graft-versus-host disease (GVHD); there was no sign of toxicity. The protection against herpes simplex virus (HSV) infection was complete in the treated group when compared to the control group even in patients with high anti-HSV antibody titres. The same protection was observed against cytomegalovirus (CMV) infection. The incidence of HSV and CMV was the same in both groups after treatment ended. This study confirms the efficacy of acyclovir against HSV infection and possibly against CMV infection when it is given prophylactically after bone marrow transplantation.
在一项双盲对照研究中，对39例连续接受骨髓移植的患者进行了口服阿昔洛韦与安慰剂的比较。移植后第8天至第35天，每6小时给予200毫克剂量。药代动力学研究表明，尽管存在与放化疗或肠道移植物抗宿主病（GVHD）相关的肠道损伤，该药物仍具有良好的吸收；未出现毒性迹象。与对照组相比，治疗组对单纯疱疹病毒（HSV）感染的防护是完全的，即使在抗HSV抗体滴度高的患者中也是如此。对巨细胞病毒（CMV）感染也观察到了同样的防护效果。治疗结束后，两组中HSV和CMV的发病率相同。这项研究证实了骨髓移植后预防性给予阿昔洛韦对HSV感染有效，可能对CMV感染也有效。
